The global radiodermatitis market is projected to grow at a CAGR of 3.7% between 2021 and 2026, to attain USD 570 million by 2026. There are two primary players, BMG Pharma S.p.A. and Stratpharma AG, among others.
Radiodermatitis is one of the frequent side effects of cancer treatment (especially breast, head, and neck cancers) or interventional radiology. The market is seeing a significant rise with an increasing number of people being affected by cancer and hence increased use of radiotherapy for treatment, proportionally influencing the radiodermatitis market. There is an increase in demand for the elimination of therapy-related side effects, which also works in favour of the radiodermatitis market. North America is expected to be the leading region of this market due to the increasing prevalence of cancer in the United States. Increasing public and private investments in the Asia Pacific region is also predicted to help the radiodermatitis market grow. The other regional market for the product includes Europe, Latin America, the Middle East, and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The expanding number of public and private healthcare organisations actively striving to improve awareness about radiodermatitis management and treatment is one of the high impact rendering elements for this sector. Furthermore, these organisations provide guidelines and recommendations on how to effectively treat the ailment, which is projected to boost the industry's growth potential throughout the forecast period. The expanding number of clinical trials being conducted to examine the efficacy of a wide range of radiodermatitis therapy items is likely to expand the market's product pipeline.BMG Pharma S.p.A.
Headquarters: Milano, Italy
BMG Pharma is an Italy-based B2B biotech company that operates as a pharmaceutical company and supports oral care, dermatology, and supportive cancer care. BMG has developed numerous patented products and functional ingredients to address specific needs by out-licensing its products to a global network of partners.
Headquarters: Basel, Switzerland
Stratpharma AG is one of the most formidable players in the radiodermatitis treatment market. The company specialises in the development and commercialisation of medical devices for dermatology, plastic surgery, burns, wounds, and scar management. Stratpharma is extending its focus by developing a range of innovative products for topical dermatology. These new products will extend upon the immediate focus on the scar and late stage wound healing.
*We at Expert Market Research always thrive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.